# ClinicalTrials.gov record NCT02276196

> PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide.

- Evidence object: `story:clinicaltrials-gov-nct02276196-lixisenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02276196-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02276196-lixisenatide-v1.json
- Content SHA-256: `ac92610f40218dcbaa793d6aa07432b817e89422235499df328edb7d311c262d`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02276196 ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02276196-2016-04-29-4d69686a040e`](#source-ctg-observation-nct02276196-2016-04-29-4d69686a040e))

## Sources

<a id="source-ctg-observation-nct02276196-2016-04-29-4d69686a040e"></a>
- **ClinicalTrials.gov record NCT02276196 · retained source version 2016-04-29:4d69686a040e223cc2cccf74e887ecc2fc0e57230db87247fba79e1f3ed4c101** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02276196) (`ctg-observation-nct02276196-2016-04-29-4d69686a040e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02276196." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02276196-lixisenatide-v1.json SHA-256: ac92610f40218dcbaa793d6aa07432b817e89422235499df328edb7d311c262d.